MPM kicks off a new I/O play­er with $44.5M round and a new un­der­stand­ing of the T cell re­cep­tor

Af­ter run­ning in stealth mode for more than a year gain­ing bet­ter un­der­stand­ing of the com­plex struc­ture of sub­units in­volved in the T cell re­cep­tor, TCR² has now jumped in­to view in Cam­bridge, MA with a $44.5 mil­lion start­up round and some big plans to make some orig­i­nal progress in im­muno-on­col­o­gy.

Gar­ry Men­zel, the for­mer COO at Reg­u­lus, has tak­en charge as the new CEO. He’s team­ing up with ex-Mer­ck KGaA sci­en­tist Robert Hofmeis­ter, who’s cred­it­ed with a se­nior role in de­vel­op­ing that com­pa­ny’s PD-L1 check­point, and Patrick Baeuer­le, the for­mer CSO at Mi­cromet.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.